

**S1 Table. Specific adverse events**

Indication <i>Source</i>	SOF-based and comparator strategies	Patients with adverse events								
		Nausea	Vomiting	Pruritus	Rash	Anaemia	Thrombocytopenia	Neutropenia	Depression	CNS
GT 1 TN IE [13, 57, 58]	SOF + PegIFN2a + RBV for 12 wks	-	-	-	-	1.7%#	-	-	-	-
	PegIFN2a/2b + RBV for 48 wks	1%	-	0.1%	0.1%	49.8%#	0.6%	14.7%	0.3%	0.9%
	TEL + PegIFN2a + RBV for 24/48 wks	1%	-	1.3%	4.8%	99.6%§	2.5%	10.3%	-	0.5%
	BOC + PegIFN2b + RBV for 24/48 wks	-	-	-	-	1.6%§	-	0.3%	0.3%	1%
GT 1 TN II [59]	SOF + RBV for 24 wks	0.8%	0.4%	-	-	1.7%#	-	-	-	-
	NT	-	-	-	-	-	-	-	-	-
GT 2 TN IE [13]*	SOF + RBV for 12 wks	-	-	-	-	1.2%§	-	-	-	-
	PegIFN2a/2b + RBV for 24 wks	-	-	-	-	-	-	-	-	-
GT 2 TN II [12]	SOF + RBV for 12 wks	-	-	-	-	0.6%§	-	-	-	-
	NT	-	-	-	-	-	-	-	-	-
GT 3 TN IE [13, 16, 60, 61]	SOF + RBV for 24 wks	0.8%	0.4%	-	-	1.6%§	-	-	-	-
	SOF + PegIFN2a + RBV for 12 wks	-	-	-	-	0.6%§	-	-	-	-
	PegIFN2a/2b + RBV for 24 wks	-	-	-	-	-	-	-	-	-
GT 3 TN II [60]	SOF + RBV for 24 wks	0.8%	0.4%	-	-	1.6%§	-	-	-	-
	NT	-	-	-	-	-	-	-	-	-
GT 3 TE IE [16, 60, 62, 63]	SOF + RBV for 24 wks	0.8%	0.4%	-	-	1.6%§	-	-	-	-
	SOF + PegIFN2a + RBV for 12 wks	-	-	-	-	0.6%§	-	-	-	-
	PegIFN2a/2b + RBV for 48 wks	-	-	-	-	-	-	-	-	-
GT 3 TE II [60]	SOF + RBV for 24 wks	0.8%	0.4%	-	-	1.6%§	-	-	-	-
	NT	-	-	-	-	-	-	-	-	-
GT 4 TN [13]	SOF + PegIFN2a + RBV for 12 wks	-	-	-	-	0.6%*	-	-	-	-
	PegIFN2a/2b + RBV for 48 wks	-	-	-	-	-	-	-	-	-

BOC, boceprevir; GT, genotype; IE, interferon eligible; II, interferon ineligible; NA, not available; PegIFN, pegylated interferon; RBV, ribavirin; SOF, sofosbuvir; SVR, sustained virological response; TE, treatment-experienced; TEL, telaprevir; TN, treatment-naïve

# 1% erythropoietin and 0.7% blood transfusions

§ equally distributed between erythropoietin and blood transfusions